BWA
AVDL

Basecamp Wealth Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

Basecamp Wealth Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8
Closed -$172 – 2029
2025
Q4 		$172 Buy
+8
New +$155 ﹤0.01% 1708

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Basecamp Wealth Advisors's AVDL Position: Q1 2026 in Review

Basecamp Wealth Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 8 shares — an estimated $172 sold.

Basecamp Wealth Advisors first reported a position in AVDL in Q4 2025 and held it in 1 quarter. The position peaked at $172 in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Basecamp Wealth Advisors reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Basecamp Wealth Advisors sold 8 Avadel Pharmaceuticals shares in Q1 2026, an estimated $172.
  • Basecamp Wealth Advisors first reported a position in Avadel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Basecamp Wealth Advisors's Avadel Pharmaceuticals position peaked at $172 in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q1 2026, filed 24 Jun 2026.